8-K: Microbot Medical Announces Positive Results from ACCESS-PVI Pivotal Trial for LIBERTY Robotic System

Microbot Medical reports 100% success in robotic navigation and a 92% reduction in radiation exposure in its ACCESS-PVI pivotal trial using the LIBERTY Endovascular Robotic System.

Summary

• Microbot Medical Inc. announced the results from its ACCESS-PVI pivotal trial at the Society of Interventional Radiology (SIR) annual meeting.
• The trial evaluated the LIBERTY Endovascular Robotic System.
• The study achieved 100% successful robotic navigation in all 20 cases, meeting the primary endpoint.
• There were no Adverse Device Events (ADE) reported during the follow-up period.
• The study showed a mean 92% relative reduction in radiation exposure for the operator.
• The median robotic navigation time to target was 3 minutes.
• Participating physicians reported a 100% satisfaction rate with LIBERTY's performance.

Sentiment

Score: 9

Explanation: The document presents overwhelmingly positive results from a pivotal clinical trial, with high success rates, significant safety improvements, and positive feedback from physicians. The management's comments are also optimistic, indicating confidence in the product's future market reception.

Positives

• The ACCESS-PVI trial achieved a 100% success rate in robotic navigation, meeting the primary endpoint.
• The LIBERTY system significantly reduced radiation exposure for operators by 92%.
• There were no adverse device events reported during the trial.
• The median robotic navigation time was only 3 minutes, indicating efficiency.
• Physicians reported 100% satisfaction with the LIBERTY system's performance.

Risks

• The LIBERTY system is still an investigational device and requires FDA 510(k) clearance before it can be sold in the U.S.
• The company's future success depends on obtaining additional working capital.
• Regulatory approvals are subject to uncertainty, including potential changes at the FDA.
• Political, social, and geopolitical conditions, including hostilities between Israel and neighboring countries, could pose risks.
• The company faces risks related to maintaining intellectual property rights.

Future Outlook

Microbot Medical is shifting its focus to building commercial capabilities and preparing for the launch of the LIBERTY system, pending FDA clearance. The company is confident that LIBERTY will be well received in the market.

Management Comments

• 'The ACCESS-PVI data and the performance of the system throughout the study reflect the hard work that the team has put into LIBERTY over the past few years,' commented Harel Gadot, Chairman, CEO and President.
• 'We are extremely pleased with the results in all aspects. As we shift focus to building our commercial capabilities and preparing for launch, we are confident that LIBERTY will be well received in the market.'
• Dr. Juan Diaz-Cartelle, the Company's Chief Medical Officer, commented that they are very satisfied with the clinical data and the investigators' feedback regarding the short learning curve and intuitive operation of the device.
• Dr. Diaz-Cartelle stated that they are looking forward to working with interventional physicians and staff upon FDA's clearance.

Industry Context

The announcement positions Microbot Medical as a potential disruptor in the endovascular robotics field, offering a single-use, fully disposable system. This addresses the traditional barriers to accessing advanced robotic systems, potentially improving the quality of care for patients and providers globally.

Comparison to Industry Standards

• The 92% reduction in radiation exposure is a significant improvement compared to traditional endovascular procedures, potentially setting a new benchmark for operator safety.
• Competitors in the robotic surgery space include Intuitive Surgical (da Vinci system) and Stryker (Mako system), but these are primarily focused on other surgical areas, not endovascular procedures.
• The 100% success rate in robotic navigation suggests a high level of precision and reliability, which could be a key differentiator for LIBERTY.

Stakeholder Impact

• Shareholders may react positively to the successful trial results.
• Employees may be motivated by the positive outcomes and the company's progress towards commercialization.
• Customers (physicians and hospitals) could benefit from the improved safety and efficiency of the LIBERTY system.
• Patients could benefit from reduced radiation exposure and potentially improved outcomes.

Next Steps

• Microbot Medical will focus on building commercial capabilities.
• The company will prepare for the launch of the LIBERTY system pending FDA clearance.
• Microbot Medical will work with interventional physicians and staff upon FDA clearance.

Key Dates

Keywords

LIBERTY Endovascular Robotic System, robotic navigation, radiation exposure, ACCESS-PVI trial, Microbot Medical, endovascular robotics, medical technology